An expert from Sino Biological explains how scalable human-based systems are empowering organoid research
Organoids, or miniature organ-like structures derived from stem cells, have emerged as transformative tools in biomedical research. Unlike traditional two-dimensional (2D) cell cultures, organoids possess a three-dimensional (3D) architecture and multiple cell types, closely mimicking the structural and functional properties of native organs. This makes them highly versatile, scalable platforms for studying human biology in a controlled laboratory environment.
As regulatory landscapes evolve, the demand for these models is surging. In April 2025, the US Food and Drug Administration (FDA) announced plans to phase out certain animal testing requirements, explicitly promoting organoids as superior, human-based alternatives for drug development. With over 180 organoid-related clinical studies registered by mid-2025, the industry is rapidly transitioning toward these high-fidelity systems for drug sensitivity testing and precision medicine.
Technical hurdles in organoid culture
Despite their potential, the path from bench to bedside is hindered by persistent technical challenges:
• Batch-to-batch variability that compromises experimental reproducibility.
• Insufficient tissue maturation and limited scalability.
• Restricted access to clinically compatible, high-performance reagents.
• Endotoxin contamination, which can activate innate immune signaling, alter cellular metabolism, and induce stress responses, ultimately confounding drug response data.
Sino Biological’s 3D organoid research solutions
To address these bottlenecks, Sino Biological offers a comprehensive portfolio of high-quality cytokines, growth factors, small molecules, and marker antibodies that are essential for organoid culture and characterisation. The company’s research solutions are optimised for nearly 30 popular physiological and tumor organoid models, providing robust support for oncology, disease modeling, and drug screening.
For example, Fudan University’s Jianqing Liang, PhD, and his colleagues used Sino Biological’s recombinant human EGF protein (Cat#: 10605-HNAE) to establish an optimal culture system for human fetal thyroid organoids hFTOs. Figure 2A depicts the schematic diagram of the digestion and seeding of fetal thyrocytes, and the culture medium of hFTOs, while Figure 2B represents the time point bright field images of hFTOs.
To further support the scientific community, Sino Biological offers a consolidated hub of technical guidelines, brochures, and expert-led webinars designed to streamline the organoid research workflow.
Ensuring culture integrity
In organoid culture systems, recombinant cytokines and growth factors play central roles in directing stem cell differentiation, maintaining tissue identity, and sustaining long-term growth. However, trace levels of endotoxin contamination can profoundly disrupt three-dimensional cultures by activating innate immune signaling pathways, altering cellular metabolism, and inducing stress responses or cell death. Such unintended effects compromise experimental reproducibility, obscure true disease phenotypes, and confound drug response data, particularly in sensitive, patient-derived organoid models.
Sino Biological provides ProPure endotoxin-free proteins for researchers to establish robust and translationally relevant organoid platforms. These highly purified preparations minimise inflammatory artifacts, reduce batch-to-batch variability, and enable consistent lineage specification across large-scale cultures. In high-throughput drug screening and preclinical studies, these reagents help ensure that observed biological responses arise from therapeutic candidates rather than culture-induced artifacts, supporting confident data interpretation and regulatory-facing research workflows.
Conclusion
Organoid technology is reshaping disease modeling and drug discovery by providing physiologically relevant, human-based platforms. Overcoming challenges such as variability, limited scalability, and endotoxin interference is essential to fully realising their translational potential. With high-quality, endotoxin-free reagents and comprehensive technical support, Sino Biological empowers researchers to build robust, reproducible organoid systems that accelerate innovation and therapeutic development, according to the company
For more information visit: www.sinobiological.com
